By CapitalSnitch Research Desk · updated Oct 11, 2026 · data from SEC filings and official Congress disclosures
Theravance Biopharma, Inc. executives and directors have only been selling lately: three insiders unloaded about $9.8 million of stock over 12 months, with no open-market purchases.
Selling on its own is common and often pre-planned (10b5-1 plans, taxes, diversification), so it matters more when it is unusually heavy or broad.
TBPH also shows up in congressional disclosures: 1 reported trade from one lawmaker in two years. Looking at the quarterly pattern: 7 quarters in a row of net selling by insiders. Insiders bought in 0 of the last 7 full quarters.
Are insiders buying or selling TBPH stock?
In the last 12 months Theravance Biopharma, Inc. insiders made open-market purchases worth about $0 and sales worth about $9.8 million. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
When was the last insider trade in TBPH?
The most recent open-market insider trade in TBPH was filed on 2026-09-17.
Has any member of Congress traded TBPH?
Yes. Members of Congress reported 1 trades in TBPH over the past two years. The full list is free on CapitalSnitch.
Free weekly email: the week's biggest insider buys and Congress trades, every Monday. No spam, one-click unsubscribe.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1).
Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).